Clinical Characteristics Of Colorectal Cancer Patients With Type 2 Diabetes Mellitus

Objective: To study the clinical characteristics of colorectal cancer patients with concurrent type 2 diabetes mellitus.Methods: We retrospectively collected clinical date of 744 patients with colorectal cancer from January 2015 to January 2018.1)Patients were divided into two groups including experimental group with type 2diabetes mellitus(n=269)and control group without type 2 diabetes mellitus(n=475).The two groups were compared in terms of age,sex,tumor site,tumor size,tumor invasion depth,lymph node metastasis,TNM stage,CA19-9 positive rate and other aspects.2)Patients with type 2diabetes mellitus were divided into two groups: the metformin using group(n=83)and the non-metformin using group(n=92).The postoperative pathological conditions of the two groups were compared.3)Patients with type 2 diabetes mellitus were divided into two groups: DM duration <5years group and ≥5 years group,and the postoperative pathological conditions of the two groups were compared.Results: There was no significant difference in tumor size,pathological type,TNM stage,lymph node metastasis,distant metastasis and positive rate of CEA between the two groups(p > 0.05).However,there were statistically significant differences in tumor site,depth of tumor invasion and positive rate of CA19-9 between the two groups.The T4 ratio in the colorectal cancer group with type 2diabetes mellitus was higher than that in the group without type 2 diabetes mellitus(P<0.05).The proportion of stage III+IV tumor,distant metastasis rate and the proportion of T4 tumor invasion depth in metformin using group were lower than those in the non-metformin using group.But the difference was not statistically significant.The proportion of T4 tumor depth was higher in the DM duration ≥5 years group than DM duration <5 years group.Conclusions: The proportion of depth of tumor invasion T4 and the positive rate of CA19-9 in colorectal cancer patients with type 2 diabetes mellitus were higher than those in the non-diabetic group.It suggests that type 2 diabetes may accelerate the progression of tumors.CA19-9 is associated with diabetes,but research is not clear.The proportion of stage III+IV tumor,distant metastasis rate and the proportion of T4 tumor invasion depth in metformin group were lower than those in the non-metformin group.It is suggested that metformin may slow down the progression of tumors and improve the prognosis accordingly,but the difference was not statistically significant.The proportion of T4 depth of tumor was higher in the DM duration ≥5 years group than DM duration <5years group,which suggested that the longer the course of diabetes,the greater the depth of tumor invasion,the faster the corresponding progression.